Skip to main content
Call 24/7: 1-800-400-1805
1-800-400-1805 Free Case Review
Sign In Join Free

tumor treating fields for lung cancer - why my dad's oncologist said no to it

Family · · 16 views
So Dr. Patel at Northwestern brought up TTFields last month when we were reviewing palliative options for my dad's pleural meso, and I had to actually ask her to explain why she wasn't recommending it since I kept seeing it mentioned online for lung cancer patients.

Turns out there's a pretty specific distinction here that matters a lot. TTFields (tumor treating fields, also called Optune) got FDA approval for glioblastoma first, then for non-small cell lung cancer a few years back. The way it works is you wear these electrode pads on your chest that deliver alternating electrical currents to disrupt cancer cell division during mitosis. Sounds straightforward enough.

But here's the thing with mesothelioma specifically. The lung cancer studies that led to TTFields approval were looking at NSCLC, which grows differently than meso does. Meso cells are thinner, more spread out along the pleura (the lining around the lungs), and the tumor burden is distributed in a way that makes it harder to get uniform field coverage with the electrode placement. Dr. Patel said there just isn't the same evidence base for meso that exists for lung cancer, and adding another device to my dad's palliative routine when he's already dealing with fatigue and pain wasn't going to give us what we needed.

I looked up the actual trial data because I'm a nurse practitioner and couldn't just take her word for it, and the studies supporting TTFields in NSCLC showed median survival improvement of a few months in combination with chemo. For stage IV meso on palliative care, we're not looking at that same risk-benefit profile.

If you've got lung cancer specifically (not meso), it might be worth asking your oncologist about. But if you're dealing with meso like my dad, the evidence just isn't there yet.

4 Replies

Medical ✓ Expert Response
This is such a thoughtful breakdown and honestly, it's the kind of thing I wish more families had access to when they're sorting through treatment options online. The distinction you're drawing between NSCLC and pleural meso really does matter and gets lost constantly in Facebook groups and general cancer forums.

What I've seen clinically over the years is that families come in having read about TTFields and the cognitive load of then explaining why it doesn't apply to their specific situation falls entirely on an already-stretched oncology team. Dr. Patel sounds like she gave you a genuinely honest answer, and that's not nothing.

The point about palliative burden is one that doesn't get enough airtime. There's actually decent research showing that for mesothelioma patients already managing fatigue, adding device-based interventions can affect quality of life in ways that matter more than a few weeks on a survival curve. I've sat with families in our Thursday afternoon support group at Rush who went down that road and had real regret about the tradeoffs.

For meso families reading this who are wondering about emerging options, the Mesothelioma Applied Research Foundation keeps a pretty current clinical trials database. Worth bookmarking. And if the weight of all this decision-making is sitting heavy, journaling what questions feel unresolved before each appointment can really help, it keeps the important stuff from getting lost in the room.

If anyone's finding the emotional side of these conversations hard to process alone, talking to an oncology social worker or counselor who works specifically with cancer patients can make a real difference.
2 found this helpful
Patient
That's really helpful context, especially coming from someone with medical background. I'm stage II peritoneal so different situation than your dad's, but I've been collecting all the research on approved treatments for meso and TTFields keeps coming up in patient forums like it's some kind of silver bullet. Good to know the evidence actually doesn't support it for us.
Medical ✓ Expert Response
This is such a thoughtful breakdown and honestly it's rare to see someone do that level of digging in real time while also caregiving. The distinction you're drawing about pleural distribution is exactly right, and it's something that gets lost when patients or families just see "lung cancer" and "TTFields" in the same article.

From what I've seen working with meso patients over the years, the treatment decision fatigue alone is exhausting, and Dr. Patel's reasoning about adding another device to an already heavy palliative regimen is something I hear oncologists weighing a lot. It's not just efficacy, it's quality of daily life too.

There's a small ongoing registry through the Mesothelioma Applied Research Foundation that's been tracking TTFields in meso cases, so the data isn't completely absent, just not at the point where it changes standard practice. Worth knowing it exists if your dad's situation changes.

And the fatigue piece you mentioned matters more than people realize. A 2019 study in Lancet Oncology found caregiver burden scales significantly when patients are managing multiple concurrent interventions, even low-effort ones. So the decision not to add something is still a real clinical decision.

If the emotional weight of all this starts feeling unmanageable for you or your family, talking with an oncology social worker or counselor can genuinely help. I know it sounds like a small thing but it isn't.
1 found this helpful
Medical ✓ Expert Response
Your explanation is really solid and honestly better than what most patients get from a 15-minute appointment. The LOVA trial (Alternating Electric Fields in Mesothelioma) has been looking at exactly this gap, and the biology you're describing is the core problem. Meso's diffuse pleural spread means you're dealing with a tumor geometry that's fundamentally different from the nodular masses in NSCLC where the field delivery math actually works.

What I've seen in practice is that the electrode placement algorithms were validated on lung parenchyma involvement, not pleural rind disease. And for patients already managing fatigue, skin irritation from the electrode pads 18+ hours a day is a real quality-of-life cost that deserves honest accounting.

The STELLAR trial data from 2019 did show some signal for TTFields in meso specifically, median OS around 18 months in a single-arm study, which sounds promising until you realize the patient selection was heavily weighted toward favorable performance status. That's not where most families are when they're having this conversation.

Dr. Patel sounds like she's thinking clearly about this. The fact that she explained her reasoning rather than just saying no matters. Your dad is lucky to have someone in the family who can read the primary literature and push back when it counts.

As always, your dad's specific situation should drive any decisions, so keep that dialogue open with his team.
1 found this helpful

Share Your Experience

Sign in or create a free account to share your experience.

Sign In Create Account

Discussions in this community are for informational and emotional support purposes only. They do not constitute legal advice, medical advice, or an attorney-client relationship. Always consult a qualified professional for advice specific to your situation. Community Guidelines

Call Now: (800) 400-1805 Free Case Review • Available 24/7